Home LiteratureArticle Details
PMID: 22080837 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

LRRK2 Parkinson disease mutations enhance its microtubule association.

Human molecular genetics ·Vol. 21 ·No. 4 ·2012-02-15 ·Pages 890-9

Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, Ellisman M, Dauer WT

Abstract

Dominant missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic causes of Parkinson disease (PD) and genome-wide association studies identify LRRK2 sequence variants as risk factors for sporadic PD. Intact kinase function appears critical for the toxicity of LRRK2 PD mutants, yet our understanding of how LRRK2 causes neurodegeneration remains limited. We find that most LRRK2 PD mutants abnormally enhance LRRK2 oligomerization, causing it to form filamentous structures in transfections of cell lines or primary neuronal cultures. Strikingly, ultrastructural analyses, including immuno-electron microscopy and electron microscopic tomography, demonstrate that these filaments consist of LRRK2 recruited onto part of the cellular microtubule network in a well-ordered, periodic fashion. Like LRRK2-related neurodegeneration, microtubule association requires intact kinase function and the WD40 domain, potentially linking microtubule binding and neurodegeneration. Our observations identify a novel effect of LRRK2 PD mutations and highlight a potential role for microtubules in the pathogenesis of LRRK2-related neurodegeneration.

MeSH Terms
Animals Cells, Cultured HEK293 Cells HeLa Cells Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Mice Microtubules/metabolism Models, Biological Mutant Proteins/genetics,metabolism Mutation/genetics Parkinson Disease/genetics Protein Binding/genetics Protein Multimerization Protein Serine-Threonine Kinases/chemistry,genetics,metabolism Protein Structure, Tertiary
Chemicals
Mutant Proteins LRRK2 protein, human Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Protein Serine-Threonine Kinases
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Kett Lauren R
Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
Boassa Daniela
Ho Cherry Cheng-Ying
Rideout Hardy J
Hu Junru
Terada Masako
Ellisman Mark
Dauer William T
References (33)
33 references, click to expand
  1. The WD40 domain is required for LRRK2 neurotoxicity.
    PLoS One. 2009 Dec 24;4(12):e8463 PMID: 20041156
  2. A comparative study of Lrrk2 function in primary neuronal cultures.
    Parkinsonism Relat Disord. 2010 Dec;16(10):650-5 PMID: 20850369
  3. Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis.
    Cell Death Differ. 2006 Oct;13(10):1641-50 PMID: 16410793
  4. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
    Nat Med. 2010 Sep;16(9):998-1000 PMID: 20729864
  5. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    J Neurochem. 2008 May;105(3):1048-56 PMID: 18182054
  6. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways.
    J Biol Chem. 2000 Sep 8;275(36):27823-31 PMID: 10880512
  7. Clinical progression in Parkinson disease and the neurobiology of axons.
    Ann Neurol. 2010 Jun;67(6):715-25 PMID: 20517933
  8. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    J Neurochem. 2009 Sep;110(5):1514-22 PMID: 19545277
  9. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase.
    EMBO J. 2008 Aug 20;27(16):2239-49 PMID: 18650931
  10. Transform-based backprojection for volume reconstruction of large format electron microscope tilt series.
    J Struct Biol. 2006 May;154(2):144-67 PMID: 16542854
  11. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules.
    J Neurosci Res. 2008 Jun;86(8):1711-20 PMID: 18214993
  12. Kinase activity of mutant LRRK2 mediates neuronal toxicity.
    Nat Neurosci. 2006 Oct;9(10):1231-3 PMID: 16980962
  13. Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis.
    J Cell Biol. 1998 Jun 1;141(5):1243-53 PMID: 9606215
  14. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.
    J Biol Chem. 2008 Jun 13;283(24):16906-14 PMID: 18397888
  15. The familial Parkinsonism gene LRRK2 regulates neurite process morphology.
    Neuron. 2006 Nov 22;52(4):587-93 PMID: 17114044
  16. Genome-wide association study reveals genetic risk underlying Parkinson's disease.
    Nat Genet. 2009 Dec;41(12):1308-12 PMID: 19915575
  17. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.
    Hum Mol Genet. 2009 Nov 1;18(21):4022-34 PMID: 19640926
  18. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8.
    J Cell Sci. 2002 Jul 1;115(Pt 13):2757-70 PMID: 12077366
  19. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.
    Neuron. 2004 Nov 18;44(4):601-7 PMID: 15541309
  20. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.
    Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1499-504 PMID: 18230735
  21. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
    Biochem J. 2010 Sep 15;430(3):405-13 PMID: 20659021
  22. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.
    Nat Genet. 2009 Dec;41(12):1303-7 PMID: 19915576
  23. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.
    Neurochem Res. 2007 Oct;32(10):1700-8 PMID: 17440812
  24. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
    Nat Rev Neurosci. 2010 Dec;11(12):791-7 PMID: 21088684
  25. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations.
    Parkinsonism Relat Disord. 1997 Nov;3(3):125-39 PMID: 18591067
  26. Axonal dynactin p150Glued transports caspase-8 to drive retrograde olfactory receptor neuron apoptosis.
    J Neurosci. 2005 Jun 29;25(26):6092-104 PMID: 15987939
  27. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
    Hum Mol Genet. 2007 Jan 15;16(2):223-32 PMID: 17200152
  28. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ß.
    J Neurosci. 2010 Sep 29;30(39):13138-49 PMID: 20881132
  29. Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate bcl10-induced NF-kappaB activation.
    J Cell Biol. 2000 Mar 20;148(6):1131-40 PMID: 10725326
  30. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.
    Neurobiol Dis. 2006 Aug;23(2):329-41 PMID: 16750377
  31. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.
    J Neurosci. 2009 Nov 4;29(44):13971-80 PMID: 19890007
  32. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration.
    J Neurosci. 2009 Jan 28;29(4):1011-6 PMID: 19176810
  33. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Biochem J. 2007 Jul 15;405(2):307-17 PMID: 17447891
Article Info
Journal
Human molecular genetics
Abbr.
Hum Mol Genet
ISSN
1460-2083
Published
2012-02-15
Epub
2011-00-11
Pages
890-9
Language
English
Region
England
NLM ID
9208958
PMCID
PMC3263991
Subset
IM
Grants
NCRR NIH HHS · P41 RR004050 · United States
NINDS NIH HHS · R01 NS061098-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]